European Union´s Horizon 2020 – Lipum2019-07-05T11:00:21+00:00


Novel Target for Treatment of Chronic Inflammatory Diseases — Notid

1408, 2019

Lipum invites to shareholders meeting

August 14th, 2019|

On August 28, Lipum shareholders will meet at Clarion Hotel Arlanda Airport. The recent progress and plans for the future will be presented and discussed. More detailed information will be sent out in personal mail. Warm welcome!

1406, 2019

Kallelse till årsstämma i Lipum AB

June 14th, 2019|

Aktieägarna i Lipum AB, org. nr. 556813-5999 (“Lipum”), kallas härmed till årsstämma fredagen den 28 juni 2019, kl. 09:00 på Tvistevägen 48C i Umeå. […]

1705, 2019

Getting roasted by investors

May 17th, 2019|

As a Horizon 2020 beneficiary we are invited to the SME Instrument Phase 2 Welcome Day organized by the European Innovation Council (EIC) Pilot in Brussels, May 22-23. Besides business networking the agenda includes: “Get roasted by investors – ready to go?”, “Success story from SME Instrument Innovator” and “Learn [...]

2103, 2019

Lipum attracts interest from life science leaders

March 21st, 2019|

Lipum is attending two significant events in Vienna next week. At the RESI Europe and the BIO-Europe Spring meetings we will meet with key decision makers from the pharma and venture capital segments. These events take place March 25-27 and provides an opportunity to meet, please contact us and learn [...]

European Commission Horizon 2020
SME Instrument phase 1 No 744248
SME Instrument phase 2 No 829741

Project title:
Novel Target for Treatment of Chronic Inflammatory Diseases

Project budget:
3.2 M€

Funding from the EU:
2.2 M€